Actinium-225 PSMA agents
Alpha-emitting PSMA drugs that produce responses even after Pluvicto fails, held back mainly by isotope supply.
Novartis (225Ac-PSMA-617, phase 3 AcTION), Bayer (225Ac-PSMA-Trillium with albumin binder, PAnTHA phase 1 at ASCO GU 2026), Fusion/AstraZeneca (FPI-2265, 225Ac-PSMA-I&T, phase 3 AlphaBreak), and academic 225Ac-PSMA data from South Africa and Germany. Xerostomia from salivary uptake is dose-limiting.
1.Radioligand circulates and binds PSMA on tumour cells
- Route
- IV infusion
- Schedule
- Trial regimens ~100 kBq/kg every 6-8 weeks
- Monitoring
- Salivary gland toxicity (xerostomia), renal function, blood counts
Source: clinicaltrials.gov. Doses are for orientation; the current label governs.
Compare all products across the US, EU, UK, Japan, China and Australia →
- Jun 2024Filing / dealUS
AstraZeneca completes Fusion Pharmaceuticals acquisition; FPI-2265 phase 3 planned source
| Adverse event |
|---|
| Xerostomia |
| Anaemia |
| Thrombocytopenia |
| Renal toxicity |
Dose-limiting in academic series. Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
| Country | Reimbursement | List price | Assistance |
|---|---|---|---|
| United States | Investigational (phase 3) | not disclosed | — |
| Germany | Compassionate use at selected centres (Heidelberg and others) | not disclosed | — |
List prices are manufacturer or Medicare figures where publicly disclosed; net prices after rebates are usually lower. Reimbursement changes; check the payer.
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Actinium-225 PSMA agents" OR ABSTRACT:"Actinium-225 PSMA agents" OR TITLE:"225Ac-PSMA-617" OR ABSTRACT:"225Ac-PSMA-617" OR TITLE:"225Ac-PSMA-I&T" OR ABSTRACT:"225Ac-PSMA-I&T" OR TITLE:"BAY 3563254 Trillium" OR ABSTRACT:"BAY 3563254 Trillium") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Actinium-225 PSMA agents, not a curated reading list.
Pages like this
not linked directly; found by shared links- CompanyTerraPower Isotopes
Shares Recover legacy radium-226 sources worldwide as the feedstock for actinium-225, Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy, Manufacturing cost and time for living and radioactive medicines.
- ProductActinium-225 DOTATATE
Shares Recover legacy radium-226 sources worldwide as the feedstock for actinium-225, Beta radioligand → alpha radioligand, Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy.
- CompanyOrano Med
Shares Recover legacy radium-226 sources worldwide as the feedstock for actinium-225, Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy, Manufacturing cost and time for living and radioactive medicines.
- TrialVISION
Shares Radiopharmaceutical roadmap: iodine → lutetium → actinium, PSMA, Manufacturing cost and time for living and radioactive medicines, Prostate cancer.
- TermAlpha vs beta emitters
Shares Alpha-emitting PSMA therapy at first metastatic diagnosis, Beta radioligand → alpha radioligand, Targeted alpha therapy, Manufacturing cost and time for living and radioactive medicines.
- ProductLutetium-177 vipivotide tetraxetan
Shares Alpha-emitting PSMA therapy at first metastatic diagnosis, Beta radioligand → alpha radioligand, Radiopharmaceutical roadmap: iodine → lutetium → actinium, PSMA.
- ProductGallium-68 gozetotide (PSMA-11)
Shares PSMA, Novartis, Prostate cancer.
- CompanyITM Isotope Technologies Munich
Shares Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy, Manufacturing cost and time for living and radioactive medicines.